These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24138309)

  • 1. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
    DiNardo CD; Patel KP; Garcia-Manero G; Luthra R; Pierce S; Borthakur G; Jabbour E; Kadia T; Pemmaraju N; Konopleva M; Faderl S; Cortes J; Kantarjian HM; Ravandi F
    Leuk Lymphoma; 2014 Aug; 55(8):1925-9. PubMed ID: 24138309
    [No Abstract]   [Full Text] [Related]  

  • 2. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
    Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
    Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
    [No Abstract]   [Full Text] [Related]  

  • 4. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.
    Perugini M; Iarossi DG; Kok CH; Cummings N; Diakiw SM; Brown AL; Danner S; Bardy P; Bik To L; Wei AH; Lewis ID; D'Andrea RJ
    Leukemia; 2013 Jul; 27(7):1588-92. PubMed ID: 23187294
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
    Emadi A; Faramand R; Carter-Cooper B; Tolu S; Ford LA; Lapidus RG; Wetzler M; Wang ES; Etemadi A; Griffiths EA
    Am J Hematol; 2015 May; 90(5):E77-9. PubMed ID: 25651001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
    Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
    Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets.
    Brower V
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26864927
    [No Abstract]   [Full Text] [Related]  

  • 11. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
    Eisfeld AK; Kohlschmidt J; Mrózek K; Blachly JS; Nicolet D; Kroll K; Orwick S; Carroll AJ; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Leukemia; 2016 Nov; 30(11):2254-2258. PubMed ID: 27435003
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
    Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
    Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
    Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
    Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
    Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
    Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Brambati C; Galbiati S; Xue E; Toffalori C; Crucitti L; Greco R; Sala E; Crippa A; Chiesa L; Soriani N; Mazzi B; Tresoldi C; Stanghellini MT; Peccatori J; Carrabba MG; Bernardi M; Ferrari M; Lampasona V; Ciceri F; Vago L
    Haematologica; 2016 Apr; 101(4):e157-61. PubMed ID: 26703962
    [No Abstract]   [Full Text] [Related]  

  • 19. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
    Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
    Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
    Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
    Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.